BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 15585638)

  • 1. Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice.
    Yezhelyev MV; Koehl G; Guba M; Brabletz T; Jauch KW; Ryan A; Barge A; Green T; Fennell M; Bruns CJ
    Clin Cancer Res; 2004 Dec; 10(23):8028-36. PubMed ID: 15585638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer.
    Ischenko I; Guba M; Yezhelyev M; Papyan A; Schmid G; Green T; Fennell M; Jauch KW; Bruns CJ
    Angiogenesis; 2007; 10(3):167-82. PubMed ID: 17486419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of PDGFR phosphorylation and Src and Akt activity by GN963 leads to therapy of human pancreatic cancer growing orthotopically in nude mice.
    Baker CH; Trevino JG; Summy JM; Zhang F; Caron A; Nesbit M; Gallick GE; Fidler IJ
    Int J Oncol; 2006 Jul; 29(1):125-38. PubMed ID: 16773192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.
    Solorzano CC; Baker CH; Bruns CJ; Killion JJ; Ellis LM; Wood J; Fidler IJ
    Cancer Biother Radiopharm; 2001 Oct; 16(5):359-70. PubMed ID: 11776753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
    Bruns CJ; Harbison MT; Davis DW; Portera CA; Tsan R; McConkey DJ; Evans DB; Abbruzzese JL; Hicklin DJ; Radinsky R
    Clin Cancer Res; 2000 May; 6(5):1936-48. PubMed ID: 10815919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma.
    Solorzano CC; Baker CH; Tsan R; Traxler P; Cohen P; Buchdunger E; Killion JJ; Fidler IJ
    Clin Cancer Res; 2001 Aug; 7(8):2563-72. PubMed ID: 11489840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.
    Bruns CJ; Solorzano CC; Harbison MT; Ozawa S; Tsan R; Fan D; Abbruzzese J; Traxler P; Buchdunger E; Radinsky R; Fidler IJ
    Cancer Res; 2000 Jun; 60(11):2926-35. PubMed ID: 10850439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth.
    Nagaraj NS; Washington MK; Merchant NB
    Clin Cancer Res; 2011 Feb; 17(3):483-93. PubMed ID: 21266529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.
    Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
    Clin Cancer Res; 2004 Apr; 10(7):2307-18. PubMed ID: 15073106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration of optimal biological dose and schedule of interferon alpha combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice.
    Solorzano CC; Hwang R; Baker CH; Bucana CD; Pisters PW; Evans DB; Killion JJ; Fidler IJ
    Clin Cancer Res; 2003 May; 9(5):1858-67. PubMed ID: 12738744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.
    Conrad C; Ischenko I; Köhl G; Wiegand U; Guba M; Yezhelyev M; Ryan AJ; Barge A; Geissler EK; Wedge SR; Jauch KW; Bruns CJ
    Anticancer Drugs; 2007 Jun; 18(5):569-79. PubMed ID: 17414626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TGF-β Signal Transduction in Pancreatic Carcinoma Cells is Sensitive to Inhibition by the Src Tyrosine Kinase Inhibitor AZM475271.
    Bartscht T; Rosien B; Rades D; Kaufmann R; Biersack H; Lehnert H; Ungefroren H
    Anticancer Agents Med Chem; 2017; 17(7):966-972. PubMed ID: 27671303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
    Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
    Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer.
    Dosch AR; Dai X; Reyzer ML; Mehra S; Srinivasan S; Willobee BA; Kwon D; Kashikar N; Caprioli R; Merchant NB; Nagathihalli NS
    Mol Cancer Res; 2020 Apr; 18(4):623-631. PubMed ID: 31949002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice.
    Bruns CJ; Shrader M; Harbison MT; Portera C; Solorzano CC; Jauch KW; Hicklin DJ; Radinsky R; Ellis LM
    Int J Cancer; 2002 Nov; 102(2):101-8. PubMed ID: 12385004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer.
    Baker CH; Solorzano CC; Fidler IJ
    Cancer Res; 2002 Apr; 62(7):1996-2003. PubMed ID: 11929816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.
    Melisi D; Ishiyama S; Sclabas GM; Fleming JB; Xia Q; Tortora G; Abbruzzese JL; Chiao PJ
    Mol Cancer Ther; 2008 Apr; 7(4):829-40. PubMed ID: 18413796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matuzumab short-term therapy in experimental pancreatic cancer: prolonged antitumor activity in combination with gemcitabine.
    Kleespies A; Ischenko I; Eichhorn ME; Seeliger H; Amendt C; Mantell O; Jauch KW; Bruns CJ
    Clin Cancer Res; 2008 Sep; 14(17):5426-36. PubMed ID: 18765534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice.
    Kedar D; Baker CH; Killion JJ; Dinney CP; Fidler IJ
    Clin Cancer Res; 2002 Nov; 8(11):3592-600. PubMed ID: 12429651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. {Gamma}-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment.
    Kunnumakkara AB; Sung B; Ravindran J; Diagaradjane P; Deorukhkar A; Dey S; Koca C; Yadav VR; Tong Z; Gelovani JG; Guha S; Krishnan S; Aggarwal BB
    Cancer Res; 2010 Nov; 70(21):8695-705. PubMed ID: 20864511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.